Clinical Trials

28 enrolled

Esophageal Neoplasms

NCT07443397 2026-03-02

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Phase 3 Recruiting

134 enrolled

Whole-Brain Radiotherapy

NCT03016819 2026-02-25

APROMISS

Phase 3 Recruiting

325 enrolled

Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

39 enrolled

HER2-Negative Breast Cancer

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Colorectal Neoplasms

NCT06662006 2026-02-06

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

56 enrolled

Pancreatic Neoplasms

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

118 enrolled

Breast Neoplasms

NCT06352008 2025-11-20

To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Phase 1/2 Recruiting

57 enrolled

CNS

Craniopharyngioma

NCT06767813 2025-09-19

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

80 enrolled

Pancreatic Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06258642 2025-08-20

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Phase NA Recruiting

39 enrolled

Small Cell Lung Carcinoma

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

35 enrolled

Breast Neoplasms

NCT04136535 2025-07-22

PCA

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07037680 2025-07-09

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07025174 2025-06-17

SAIB

60 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

411 enrolled